Pereira, Anamaria Falcão
Lisboa, Mario Roberto Pontes
de Freitas Alves, Bruno Wesley
da Silva, Cristiane Maria Pereira
Dias, Diego Bernarde Souza
de Menezes, Karoline Luanne Santos
Cesário, Francisco Rafael Alves Santana
de França, Jonas Costa
de Oliveira, Amanda Rocha
Hallak, Jaime Eduardo Cecilio
Zuardi, Antonio Waldo
Crippa, José Alexandre
de Alencar, Nylane Maria Nunes
Lima-Júnior, Roberto César Pereira
Vale, Mariana Lima
Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (PR2-0101-00054.01.00/15)
Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico (PR2-0101-00054.01.00/15)
Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (2008/09009-2)
Article History
Received: 7 April 2021
Revised: 3 November 2021
Accepted: 5 November 2021
First Online: 18 November 2021
Declarations
:
: All procedures conducted in studies involving animals were in accordance with the ethical standards of the institution where the studies were performed. The study was approved by the Ethics Committee on the Use of Animals of the Federal University of Ceará (number: 41/2016).
: JAC is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) – National Health and Medical Research Council (NHMRC). JAC and JEH have received travel support to attend scientific meetings and personal consultation fees from BSPG-Pharm. JAC, JEH, and AWZ are coinventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023,” Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi AW, Kapczinski F, Hallak JEC, Guimarães FS, Crippa JAS, Breuer A). Universidade de São Paulo (USP) has licensed this patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1) and has an agreement with Prati-Donaduzzi to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JAC, JEH, and AWZ are coinventors of the patent “Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same,” INPI on September 16, 2016 (BR 112018005423–2). The other authors declare that they have no competing interests.